| 3.76 -0.1 (-2.59%) | 10-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.97 | 1-year : | 5.81 |
| Resists | First : | 4.26 | Second : | 4.97 |
| Pivot price | 1.7  |
|||
| Supports | First : | 1.71 | Second : | 0.13 |
| MAs | MA(5) : | 3.84 |
MA(20) : | 1.36 |
| MA(100) : | 0.58 |
MA(250) : | 0.54 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 92.2 |
D(3) : | 93.3 |
| RSI | RSI(14): 82 |
|||
| 52-week | High : | 4.26 | Low : | 0.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SCNX ] has closed below upper band by 20.9%. Bollinger Bands are 1544.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.84 - 3.87 | 3.87 - 3.89 |
| Low: | 3.6 - 3.63 | 3.63 - 3.65 |
| Close: | 3.72 - 3.76 | 3.76 - 3.8 |
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is headquartered in Commack, New York.
Thu, 01 Oct 2026
Scienture Holdings (SCNX) Stock Drops 19% After Hours: Here's What Happened - Benzinga
Wed, 30 Sep 2026
Scienture Holdings, Inc. Announces Reverse Stock Split - The Manila Times
Wed, 30 Sep 2026
Every 25 shares are expected to become one as Scienture aims to meet Nasdaq's minimum share-price rule. - Stock Titan
Thu, 24 Sep 2026
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Tue, 15 Sep 2026
Scienture Holdings Updates Investor Presentation and Guidance - The Globe and Mail
Thu, 03 Sep 2026
Enterprise value to revenue forward of Scienture Holdings, Inc. – NASDAQ:SCNX - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 0 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 3.279e+007 (%) |
| Held by Institutions | 13.3 (%) |
| Shares Short | 1,170 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.527e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 230.8 % |
| Return on Equity (ttm) | -10.9 % |
| Qtrly Rev. Growth | 477680 % |
| Gross Profit (p.s.) | 113.4 |
| Sales Per Share | -14.29 |
| EBITDA (p.s.) | 97136.4 |
| Qtrly Earnings Growth | -2.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.27 |
| Price to Cash Flow | 9.07 |
| Dividend | 0 |
| Forward Dividend | 2.6e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|